User talk:3shalim26
3shalim26, you are invited to the Teahouse!
[edit]
|
Hi 3shalim26! Thanks for contributing to Wikipedia. Be our guest at the Teahouse! The Teahouse is a friendly space where new editors can ask questions about contributing to Wikipedia and get help from peers and experienced editors. I hope to see you there! AmaryllisGardener (I'm a Teahouse host) This message was delivered automatically by your robot friend, HostBot (talk) 17:20, 28 October 2015 (UTC) |
Welcome!
[edit]Hello, 3shalim26, and welcome to Wikipedia! My name is Ian and I work with the Wiki Education Foundation; I help support students who are editing as part of a class assignment.
I hope you enjoy editing here. If you haven't already done so, please complete the student training, which introduces you to editing and Wikipedia's core principles. You may also want to check out the Teahouse, a community of Wikipedia editors dedicated to helping new users. Below are some resources to help you get started editing.
Handouts
|
|---|
Additional Resources
|
|
If you have any questions, please don't hesitate to contact me on my talk page. Ian (Wiki Ed) (talk) 22:13, 29 October 2015 (UTC)
Outlines what content typically goes in what section. Best Doc James (talk · contribs · email) 02:16, 4 November 2015 (UTC)
Some Edits as of 11/4/15
[edit]Intro edits: “marketed under trade names”, included: It exists in tablet, elixir and solution in various strengths for oral administration” cited ECR pharmaceuticals.
Medical/Rec uses edits: Deleted the “Usage” section because it’s redundant. Copied and pasted it into the “Intro” portion. Added different formulations of the drug, noted it’s reschedule from CIII to CII. Included pregnancy and breast feeding portions. Added special population section: pregancy, breastfeeding, hepatic/renal impairment
PD edit: Removed “This conversion is only somewhat responsible for the effects of hydrocodone” since it is unclear what is meant by “effects”. Removed blood brain barrier summary since it is not cited.
Added citations to sulfation and glucoronidation, COX activity and prostaglandin. Updated half life and peak levels with better resources since the trial originally cited was conducted in chronic dialysis patients so generalizability is questionable. Serotonergic neurotransmission hypothesis has been removed since trial was conducted in rats and not humans and it has not been an established hypothesis. Added mechanism for liver damage. Regulation and proposed bans: arranged the events in chronological order.
Side effects, monitoring edits:
Reworded common side effects section. Added non common side effects below common side effects
Central Nervous System: drowsiness, confusion, lethargy, anxiety, fear, dysphoria, psychic dependence, mood changes, impairment of mental and physical performance [1] Gastrointestinal System: constipation [1] Genitourinary System: urinary retention, urethral and vesical sphincter spasm [1] Respiratory Depression: inadequate ventilation [1] Special Senses: hearing impairment, permanent hearing loss [1] Dermatological: rash, itching [1]
Added monitoring section to recommend monitoring for patients with renal and hepatic impairment
Added Black box warning and allergy warning Added interactions
Removed manufacturer section and Television section